We are live on ! Find out more
LEXX icon

Lexaria Bioscience

15 hedge funds and large institutions have $803K invested in Lexaria Bioscience in 2026 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

353% more capital inflows, than outflows

Capital inflows: $1.39M | Capital outflows: $308K

8.86% more ownership

Funds ownership: 6.65% → 15.51% (+8.9%)

48% less funds holding

Funds holding: 29 → 15 (-14)

63% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 8

88% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 16

Holders
15
Holders Change
-14
Holders Change %
-48.28%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
8
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

LEXX Hedge Fund Activity: Q3 2026 in Review

15 of the 8,224 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q3 2026, worth a combined $803K — down 13% from $924K a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of LEXX and 2 opened new positions — a net loss of 14 holders — while 8 trimmed existing stakes and 3 added.

The largest buyer was Armistice Capital, opening a new position worth an estimated $1.31M. The largest seller was Citadel Advisors, exiting entirely with an estimated $87.9K sold.

  • 15 institutional investors held Lexaria Bioscience (LEXX) as of Q3 2026, down from 29 in Q2 2026.
  • Funds reported $803K of Lexaria Bioscience stock for Q3 2026, down 13% quarter-over-quarter.
  • 2 funds opened new Lexaria Bioscience positions in Q3 2026 and 16 closed out, a net change of -14 holders.
  • The largest Lexaria Bioscience buyer in Q3 2026 was Armistice Capital, an estimated $1.31M added.
  • The largest Lexaria Bioscience seller in Q3 2026 was Citadel Advisors, an estimated $87.9K sold.

Based on aggregated 13F filings for Q3 2026.